Huining Cao
Direktor/Vorstandsmitglied bei China Nuokang Bio-Pharmaceutical, Inc.
Profil
Huining Cao is an Independent Director at China Nuokang Bio-Pharmaceutical, Inc. since 2010.
He is also currently serving as the Academic Director-Finance & Professor-Finance at Cheung Kong Graduate School of Business.
Previously, he held positions as a Professor at Carnegie Mellon University, The Ohio State University, the University of California, Berkeley, the University of California San Diego, and The University of North Carolina at Charlotte.
Dr. Cao holds a doctorate degree from the University of California, Los Angeles and Yale University.
Aktive Positionen von Huining Cao
Unternehmen | Position | Beginn |
---|---|---|
China Nuokang Bio-Pharmaceutical, Inc.
China Nuokang Bio-Pharmaceutical, Inc. Pharmaceuticals: MajorHealth Technology China Nuokang Bio-Pharmaceutical, Inc. is a biopharmaceutical company focused on the research, development, manufacture, marketing and sales of hematological and cardiovascular products. It currently sells a portfolio of fourteen products, including three principal products: Baquting, its flagship bleeding control product; Aiduo, its cardiovascular stress imaging agent; and Aiwen, its anti-arrhythmic agent. The company has also entered into an exclusive agreement for the marketing and distribution in China of Kaitong, an intravenous injectable lipid emulsion of vasodilator alprostadil for the treatment of peripheral vascular diseases, cardiocerebral microcirculation disorders and post-surgery thrombosis. Its product pipeline includes four product candidates under development that address the growing market and medical needs for hematological, cardiovascular and cerebrovascular disease diagnosis, treatment and prevention. The company was founded on November 1997 and is headquartered in Shenyang, China. | Direktor/Vorstandsmitglied | 27.08.2010 |
Cheung Kong Graduate School of Business | Corporate Officer/Principal | 13.12.2010 |
Ehemalige bekannte Positionen von Huining Cao
Unternehmen | Position | Ende |
---|---|---|
The University of North Carolina at Charlotte | Corporate Officer/Principal | - |
Carnegie Mellon University
Carnegie Mellon University Other Consumer ServicesConsumer Services Carnegie Mellon University is an American school that operates as a college or university. It is located in Pittsburgh, Pennsylvania. | Corporate Officer/Principal | - |
University of California San Diego | Corporate Officer/Principal | - |
The Ohio State University
The Ohio State University Other Consumer ServicesConsumer Services Global Factory, Inc. provides collaborative manufacturing execution systems. The firm's software gather, organize & analyze demand, production & quality data from various sources and monitor key indicators & execute business processes to control, manage & optimize distributed manufacturing operations. The company was founded in 1999 and is headquartered in Santa Clara, CA. | Corporate Officer/Principal | - |
University of California, Berkeley | Corporate Officer/Principal | - |
Ausbildung von Huining Cao
University of California, Los Angeles | Doctorate Degree |
Yale University | Doctorate Degree |
Erfahrungen
Besetzte Positionen
Aktive
Inaktive
Börsennotierte Unternehmen
Private Unternehmen
Beziehungen
Beziehungen ersten Grades
Unternehmen ersten Grades
Herr
Frau
Aufsichtsräte
Führungskräfte
Unternehmensverbindungen
Private Unternehmen | 1 |
---|---|
China Nuokang Bio-Pharmaceutical, Inc.
China Nuokang Bio-Pharmaceutical, Inc. Pharmaceuticals: MajorHealth Technology China Nuokang Bio-Pharmaceutical, Inc. is a biopharmaceutical company focused on the research, development, manufacture, marketing and sales of hematological and cardiovascular products. It currently sells a portfolio of fourteen products, including three principal products: Baquting, its flagship bleeding control product; Aiduo, its cardiovascular stress imaging agent; and Aiwen, its anti-arrhythmic agent. The company has also entered into an exclusive agreement for the marketing and distribution in China of Kaitong, an intravenous injectable lipid emulsion of vasodilator alprostadil for the treatment of peripheral vascular diseases, cardiocerebral microcirculation disorders and post-surgery thrombosis. Its product pipeline includes four product candidates under development that address the growing market and medical needs for hematological, cardiovascular and cerebrovascular disease diagnosis, treatment and prevention. The company was founded on November 1997 and is headquartered in Shenyang, China. | Health Technology |